Bimatoprost as a Treatment for Graves' Orbitopathy

Johns Hopkins University

Status and phase: Enrolling; Early Phase 1

Conditions: Graves Ophthalmopathy

Treatments: Drug: Bimatoprost Ophthalmic

Study type: Interventional

Funder types: Other

Identifiers

NCT03708627

IRB00294393

Details and patient eligibility

About

Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease

Enrollment: 3 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Graves' Ophthalmopathy with Exophthalmos/Proptosis -

Exclusion Criteria: Active Graves Disease, Currently pregnant, Taking Steroids

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

3 participants in 2 patient groups

Bimatoprost in more proptotic eye

Experimental group

Description:

Patients instill Bimatoprost in their more proptotic eye one nightly

Treatment:

Drug: Bimatoprost Ophthalmic

Control

No Intervention group

Description:

Bimatoprost is not instilled in the patient's fellow eye